PURPOSE: To review the recent major advances in the molecular and cell biology of B-cell
chronic lymphocytic leukemia (B-CLL). METHODS: We analyzed the nature of malignant B …

Introduction: Numerous biomarkers have been evaluated for the diagnosis, assessment of
disease activity, prognosis, and response to treatment in sarcoidosis. In this report, we …

Abstract The National Cancer Institute (NCI)‐sponsored Chronic Lymphocytic Leukemia
(CLL) Working Group was convened to develop a set of standardized eligibility, response …

Patients with chronic lymphocytic leukemia (CLL) are at an increasing risk of infectious
morbidity and mortality. Infections are generally due to bacteria and influenced by the …

A number of growth factors are involved in clonal haematopoietic expansion and their
clinical significance in patients with chronic myeloproliferative diseases requires further …

A NUMBER of receptors for growth factors and differentiation antigens have been found to
be secreted or released by cells. Following mononuclear cell (MNC) activation and …

Over the past decade, the introduction of nucleoside analogs and monoclonal antibodies
into the treatment of patients with chronic lymphocytic leukemia (CLL) has resulted in higher …

DAB486IL-2 is a recombinant fusion toxin in which the native receptor binding domain of
diphtheria toxin has been replaced with human interleukin-2 (IL-2). It selectively binds and …

PURPOSE This study was initiated to evaluate whether soluble CD23 (sCD23) reflects
disease activity and tumor load in B-cell chronic lymphocytic leukemia (B-CLL) and to …

Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome
of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide …